株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

自閉症 : パイプライン分析

Autism - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 232811
出版日 ページ情報 英文 138 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.97円で換算しております。
Back to Top
自閉症 : パイプライン分析 Autism - Pipeline Review, H2 2017
出版日: 2017年07月11日 ページ情報: 英文 138 Pages
概要

自閉症とは、社会性の問題やコミュニケーション障害、行動の制限性、反復性、常同性などを特徴とする神経発達障害であり、性別、家族歴、脆弱X症候群、トゥレット症候群、癲癇などが素因となります。治療法には、SSRI(選択的セロトニン再取り込み阻害剤)、抗鬱剤、抗精神病薬、鎮静剤などの投与があります。

当レポートでは、世界における自閉症治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

自閉症の概要

治療薬の開発

  • 自閉症向けパイプライン製品:概要
  • 自閉症向けパイプライン製品:比較分析

自閉症:開発中の治療薬:企業別

自閉症:開発中の治療薬:大学・研究機関別

自閉症:パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階不明の製品

自閉症:開発中の製品:企業別

自閉症:開発中の製品:大学・研究機関別

自閉症:治療薬開発に従事している企業

  • Addex Therapeutics Ltd
  • Aequus Pharmaceuticals Inc.
  • AgeneBio Inc.
  • APeT Holding BV
  • Berg LLC
  • BioCrea GmbH
  • BrainStorm Cell Therapeutics Inc.
  • Cellceutix Corporation
  • Confluence Pharmaceuticals LLC
  • Curemark, LLC
  • Domain Therapeutics SA
  • F. Hoffmann-La Roche Ltd.
  • Heptares Therapeutics Limited
  • Intra-Cellular Therapies, Inc.
  • Luc Therapeutics, Inc.
  • MedDay
  • Omeros Corporation
  • 大塚ホールディングス
  • Retrophin Inc.
  • Sage Therapeutics, Inc.
  • Saniona AB
  • 大日本住友製薬

自閉症:治療薬の評価

  • 単剤治療薬
  • コンビネーション製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (デキストロメトルファン + 硫酸キニジン)
  • ADX-71441
  • ADX-88178
  • アリピプラゾール
  • カルベトシン
  • CM-AT
  • 自閉症向け薬剤
  • ヒスタミン二塩酸塩
  • HTL-14242
  • ITI-007
  • KM-391
  • ルラシドン塩酸塩
  • MD-1103
  • niacinamide CR
  • oxytocin
  • RG-7314
  • SF-999
  • SGE-872
  • 中枢神経系障害治療用GABRA5 受容体作動薬
  • 自閉症治療用 GABAA 受容体サブユニット・アルファ5小分子作動薬
  • 自閉症治療用 GPR63標的薬
  • 自閉症・不安障害治療用オキシトシン標的薬
  • てんかん・自閉症治療用GABAA-Beta 2 受容体作動薬
  • 自閉症治療用代謝型グルタミン酸受容体4作動薬
  • 中枢神経系障害治療用 NMDA2A拮抗薬
  • 阻害剤 PI3K 自閉症・脆弱性X症候群治療用
  • 自閉症治療用/腫瘍学向け 翻訳開始因子-4E阻害剤
  • SNA-1
  • 多発性硬化症・関節リウマチ・骨関節炎・自閉症・気管支肺形成異常向け幹細胞療法
  • 神経変性疾患向け幹細胞療法
    • 製品概要
    • 作用機序
    • R&Dの進捗

最新のパイプライン動向

休止中のプロジェクト

開発中止の製品

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9502IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Autism - Pipeline Review, H2 2017, provides an overview of the Autism (Central Nervous System) pipeline landscape.

Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child's sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors), antidepressants, antipsychotics, and sedatives.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Autism - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Autism (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Autism (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Autism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 6, 4, 1, 18, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1 and 1 molecules, respectively.

Autism (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Autism (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Autism (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Autism (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Autism (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Autism (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Autism (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Autism (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Autism - Overview
    • Autism - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Autism - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Autism - Companies Involved in Therapeutics Development
    • 4D Pharma PLC
    • Addex Therapeutics Ltd
    • Aequus Pharmaceuticals Inc
    • Aevi Genomic Medicine Inc
    • AgeneBio Inc
    • Anima Biotech Ltd
    • APeT Holding BV
    • BioCrea GmbH
    • BioHealthonomics Inc
    • BrainStorm Cell Therapeutics Inc
    • Confluence Pharmaceuticals LLC
    • Coronis NeuroSciences Ltd
    • Curemark LLC
    • DRI Biosciences Corp
    • F. Hoffmann-La Roche Ltd
    • GW Pharmaceuticals Plc
    • Heptares Therapeutics Ltd
    • Immuron Ltd
    • Intra-Cellular Therapies Inc
    • Leading BioSciences Inc
    • MedDay SA
    • Omeros Corp
    • OptiNose US Inc
    • Ovensa Inc
    • Q BioMed Inc
    • Sumitomo Dainippon Pharma Co Ltd
  • Autism - Drug Profiles
    • acamprosate calcium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACT-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-71441 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-88178 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibody to Inhibit Lipopolysaccharide for Autism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aripiprazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASD-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologics for Autism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CB-0306 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CM-AT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CP-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Autism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Autism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fasoracetam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GWP-42006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • histamine dihydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HTL-14242 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMM-124E - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • L-179 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lumateperone tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lurasidone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MD-1103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • niacinamide CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NurOwn - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • oxytocin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PAM-28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Insulin Like Growth Factor 1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-7314 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SERx-519 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SF-999 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize GABRA5 Receptor for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target GPR63 for Autism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Autism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize CB1 and CB2 for Autism, Eczema and Insomnia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Translation Initiation Factor-4E for Autism and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TTA-121 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Autism - Dormant Projects
  • Autism - Discontinued Products
  • Autism - Product Development Milestones
    • Featured News & Press Releases
      • Apr 19, 2017: BrainStorm Announces Publication of NurOwn Autism Research Study
      • Feb 23, 2017: Curemark Announces Further Expansion of Clinical Sites For Its Phase 3 Clinical Trial for Children with Autism - The BlUm Study
      • Sep 22, 2016: Blum Study - A Phase 3 Clinical Trial for Children with Autism
      • Jul 20, 2016: Immuron to Cooperate with Leading Australian Universities on Autism Research
      • Feb 04, 2016: Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch
      • Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole
      • May 11, 2015: Curemark Launches New Phase III Trial in Expanded Population of Children with Autism
      • Nov 04, 2013: Curemark Begins NDA Submission for CM-AT Autism Treatment
      • Apr 23, 2013: Curemark Announces Positive Pre-NDA Meeting With FDA For New Drug Application For CM-AT For Autism
      • Aug 15, 2012: Omeros Unlocks Over Half Of Class A Orphan G Protein-Coupled Receptors
      • Aug 06, 2012: Curemark To Enroll Children 9-12 Years Of Age Into Medical Trial Of CM-AT For Children With Autism
      • May 31, 2012: Study Reports New Treatment For Irritability In Autism
      • Dec 07, 2011: Curemark Reports Positive Phase III Results Of CM-AT In Children With Autism
      • Mar 21, 2011: Curemark Completes Enrollment Of Phase III Trials For CM-AT In Autism
      • Oct 27, 2010: Curemark Adds Two Autism Trial Sites In California
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Autism, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Autism - Pipeline by 4D Pharma PLC, H2 2017
  • Autism - Pipeline by Addex Therapeutics Ltd, H2 2017
  • Autism - Pipeline by Aequus Pharmaceuticals Inc, H2 2017
  • Autism - Pipeline by Aevi Genomic Medicine Inc, H2 2017
  • Autism - Pipeline by AgeneBio Inc, H2 2017
  • Autism - Pipeline by Anima Biotech Ltd, H2 2017
  • Autism - Pipeline by APeT Holding BV, H2 2017
  • Autism - Pipeline by BioCrea GmbH, H2 2017
  • Autism - Pipeline by BioHealthonomics Inc, H2 2017
  • Autism - Pipeline by BrainStorm Cell Therapeutics Inc, H2 2017
  • Autism - Pipeline by Confluence Pharmaceuticals LLC, H2 2017
  • Autism - Pipeline by Coronis NeuroSciences Ltd, H2 2017
  • Autism - Pipeline by Curemark LLC, H2 2017
  • Autism - Pipeline by DRI Biosciences Corp, H2 2017
  • Autism - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Autism - Pipeline by GW Pharmaceuticals Plc, H2 2017
  • Autism - Pipeline by Heptares Therapeutics Ltd, H2 2017
  • Autism - Pipeline by Immuron Ltd, H2 2017
  • Autism - Pipeline by Intra-Cellular Therapies Inc, H2 2017
  • Autism - Pipeline by Leading BioSciences Inc, H2 2017
  • Autism - Pipeline by MedDay SA, H2 2017
  • Autism - Pipeline by Omeros Corp, H2 2017
  • Autism - Pipeline by OptiNose US Inc, H2 2017
  • Autism - Pipeline by Ovensa Inc, H2 2017
  • Autism - Pipeline by Q BioMed Inc, H2 2017
  • Autism - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
  • Autism - Dormant Projects, H2 2017
  • Autism - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Autism - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Autism, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top